Armstrong Fleming & Moore Inc Makes New $343,000 Investment in IQVIA Holdings Inc. $IQV

Key Points

• Armstrong Fleming & Moore Inc has made a new investment of $343,000 in IQVIA Holdings Inc, purchasing 2,177 shares during the second quarter.
• IQVIA reported earnings of $2.81 per share, surpassing analyst expectations, with quarterly revenue reaching $4.02 billion, up 5.3% from the previous year.
• Multiple brokerages have raised their price targets for IQVIA, with UBS increasing its target from $185.00 to $225.00 and maintaining a "buy" rating.

Armstrong Fleming & Moore Inc bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 2,177 shares of the medical research company's stock, valued at approximately $343,000.

A number of other institutional investors have also recently added to or reduced their stakes in IQV. Everpar Advisors LLC lifted its holdings in IQVIA by 4.6% during the 2nd quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company's stock worth $221,000 after purchasing an additional 62 shares in the last quarter. Ballentine Partners LLC raised its holdings in shares of IQVIA by 4.9% in the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock valued at $260,000 after acquiring an additional 69 shares in the last quarter. Independent Advisor Alliance raised its holdings in shares of IQVIA by 4.2% in the 1st quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company's stock valued at $318,000 after acquiring an additional 72 shares in the last quarter. Nemes Rush Group LLC raised its holdings in shares of IQVIA by 15.0% in the 1st quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock valued at $109,000 after acquiring an additional 81 shares in the last quarter. Finally, Forte Capital LLC ADV raised its holdings in shares of IQVIA by 0.3% in the 2nd quarter. Forte Capital LLC ADV now owns 26,809 shares of the medical research company's stock valued at $4,225,000 after acquiring an additional 92 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Down 0.1%

Shares of NYSE:IQV opened at $200.60 on Thursday. The stock has a fifty day simple moving average of $188.35 and a two-hundred day simple moving average of $168.04. The stock has a market capitalization of $34.10 billion, a price-to-earnings ratio of 29.03, a PEG ratio of 2.21 and a beta of 1.32. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $237.34. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The firm's quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on IQV. William Blair reissued an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. Redburn Partners set a $214.00 price objective on IQVIA in a report on Wednesday, September 3rd. Mizuho raised their price objective on IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Weiss Ratings reissued a "hold (c)" rating on shares of IQVIA in a report on Wednesday. Finally, UBS Group raised their price target on IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Eighteen research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $233.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.